Table 5 Summary table for studies reporting therapeutic impact
From: Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology
Study | Population | Outcome | New Technology n with event/N (%) | Comparator n with event/N (%) | Effect size (95Â % CI/p value) |
|---|---|---|---|---|---|
Catalano et al. (2013) [24] | Cohort observational study. Staging or follow-up of non-CNS tumours (n = 134) | Patients additional findings not identified on alternate modality | 6/134 (4.5 %) | 55/134 (41 %) | OR: 14.9 (6.1–36.1 p <0.0001) |
Patients with additional findings not identified on alternate modality affecting clinical management | 24/134 (17.9 %) | 2/134 (1.5 %) | OR: 14.4 (3.3–62.3 p <0.0001) | ||
Reiner et al. (2014) [25] | Cohort observational study. Hepatic metastases (n = 55, CRC: n = 41) | Patients additional findings not identified on alternate modality | 8/55 (9.1 %) | 0/55 (0 %) | OR: Infinity OR: Infinity |
Patients with additional findings not identified on alternate modality affecting clinical management | 5/55 (9.1Â %) | 0/55 (0Â %) | |||
Al-Nabhani et al. (2014) [7] | Cohort observational study. Staging of non-CNS tumours (n = 50) | Patients with additional findings not identified on alternate modality affecting clinical management | 4/50 (8 %) | 1/50 (2 %) | OR: 2.1 (0.36–11.9 NS) |